Latest Articles

Publication Date
Natural compounds for endometriosis and related chronic pelvic pain: A review.

Endometriosis is a chronic gynecological disorder characterized by significant chronic pelvic pain (CPP) and infertility, adversely affecting the quality of life for many women worldwide. This review aims to synthesize …

Published: Oct. 25, 2024, midnight
P2X3 and P2X2/3 Receptors Inhibition Produces a Consistent Analgesic Efficacy: A Systematic Review and Meta-Analysis of Preclinical Studies.

P2X3 and P2X2/3 receptors are promising therapeutic targets for pain treatment and selective inhibitors are under evaluation in ongoing clinical trials. Here we aim to consolidate and quantitatively evaluate the …

Published: Oct. 9, 2024, midnight
Effect of Dietary Interventions on Endometriosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

This study aimed to systematically review existing randomized clinical trials on the effect of dietary interventions on endometriosis. A search was performed on the Cochrane Central Register of Controlled Trials …

Published: Oct. 2, 2024, midnight
Levonorgestrel intrauterine system versus dienogest effect on quality of life of women with deep endometriosis: a randomized open-label clinical trial.

Women with deep infiltrating endometriosis (DIE) can benefit from the use of progestins. Our aim is to explore if levonorgestrel-releasing intrauterine system (LNG-IUS) non inferior to dienogest (DNG) in improving …

Published: Aug. 7, 2024, midnight
Rubraca sheds positive light for PARP inhibitors in endometrial cancer - Clinical Trials Arena

Rubraca sheds positive light for PARP inhibitors in endometrial cancer Clinical Trials Arena

Published: April 2, 2024, 7 a.m.
Emerging Drug Targets for Endometriosis.

Endometriosis is a chronic inflammatory disease causing distressing symptoms and requiring a life-long management strategy. The objective of this review is to evaluate endometriosis-related pathways and identify novel therapies to …

Published: Nov. 8, 2022, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!